Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastrointest Surg. Nov 27, 2022; 14(11): 1204-1218
Published online Nov 27, 2022. doi: 10.4240/wjgs.v14.i11.1204
Table 1 Extent of extended lymphadenectomy and standard lymphadenectomy in pancreatic head carcinoma
Location
Standard lymphadenectomy
Extended lymphadenectomy
Superior pyloric (No.5)OO
Inferior pyloric (No.6)OO
Anterior CHA (No.8a)OO
Posterior CHA (No.8p)XO
Celiac axis (No.9)XO
Proper hepatic artery (No.12a)XO
Bile duct (No.12b)OO
Cystic duct (No.12c)OO
Portal vein (No.12p)XO
Posterior pancreaticoduodenal (No.13a-b)OO
Origin and right side of SMA (No.14a-b)XO
Left side of SMA(No.14c-d)XO
Celiac axis to IMA (No.16a2, No.16b1)XO
Anterior pancreaticoduodenal (No.17a-b)OO
Table 2 General data between extended and standard lymphadenectomy group in pancreatic head carcinoma patients
Variables
ELD group (n = 88)
SLD group (n = 128)
P value
Gender (male/female)51/3773/550.893
Age (yr)62.1 ± 11.064.6 ± 10.00.080
TB (μmol/L)62.6 (15.3, 144.6)57.7 (12.7, 143.4)0.679
CA19-9 (U/ml)161.8 (38.5, 544.9)202.1 (44.9, 773.2)0.342
Intraoperative blood loss (mL)500 (400, 800)600 (400, 800)0.332
Operation time (h)11.1 ± 2.811.0 ± 2.90.693
Tumor size (cm)3.5 ± 1.43.5 ± 1.70.790
Tumor differentiation (poorly/ modrately& highly)25/6347/810.203
Portal vein invasion (yes/no)47/4169/590.943
Lymph node metastasis (yes/no)54/3491/370.135
Retrieved lymph node count25 (18, 35)19 (14, 28)0.001
Positive lymph node count1 (0, 4)2 (0, 3)0.614
Resection margin (R0/R1)83/5118/100.545
Postoperative chemotherapy (yes/no)48/4061/670.320
Table 3 Perioperative complications between extended and standard lymphadenectomy group in pancreatic head carcinoma patients
Variables
ELD (n = 88)
SLD (n = 128)
P value
Perioperative death 250.783
Postoperative complications27420.741
Biochemical fistula360.908
Pancreatic fistula (grade B/C)460.779
DGE9150.732
Diarrhea224< 0.001
Abdominal infection9130.987
Abdominal hemorrhage340.783
Table 4 General data between extended and standard lymphadenectomy group in pancreatic head carcinoma patients at different T stages
VariablesT1 stage
T2 stage
T3 stage
ELD group (n = 16)
SLD group (n = 28)
P value
ELD group (n = 51)
SLD group (n = 76)
P value
ELD group (n = 21)
SLD group (n = 24)
P value
Gender (male/female)10/614/140.42332/1946/300.8019/1213/110.449
Age (yr)62.8 ± 12.464.1 ± 9.70.69664.2 ± 9.864.7 ± 10.30.80156.2 ± 10.964.8 ± 9.70.001
TB (μmol/L)58.1 (16.8, 107.5)72.3 (28.1, 149.0)0.74280.8 (14.6, 149.3)60.6 (12.7, 168.7)0.88544.4 (13.0, 137.7)29.4 (10.3, 96.8)0.285
CA19-9 (U/mL)115.9 (24.0, 262.8)92.5 (38.7, 312.5)0.817152.7 (53.7, 545.9)207.0 (43.5, 1058.9)0.507180.2 (39.6, 556.4)424.5 (77.8, 1285.6)0.270
Intraoperative blood loss (mL)500 (400, 600)500 (400, 650)0.788500 (400, 800)600 (400, 800)0.310500 (400, 1000)550 (400, 1000)0.741
Operation time (h)10.8 ± 3.59.5 ± 2.90.19410.9 ± 2.511.3 ± 2.70.40411.9 ± 3.011.6 ± 3.20.746
Tumor size (cm)1.7 ± 0.41.8 ± 0.30.2743.2 ± 0.53.4 ± 0.50.1935.4 ± 1.06.1 ± 2.00.155
Tumor differentiation (poorly/moderately-highly)2/1411/170.12614/3724/520.6199/1212/120.632
Portal vein invasion (yes/no)4/126/220.91928/2345/310.63015/618/60.787
Lymph node metastasis (yes/no)10/615/130.56531/2055/210.17115/623/50.587
Retrieved lymph node count21 (18, 32)15 (12, 19)0.00426 (21, 33)23 (16, 31)0.50925 (15, 40)20 (15, 30)0.030
Positive lymph node count2 (0, 2)1 (0, 2)0.3731 (0, 4)2 (0, 4)0.5131 (0, 3)4 (1, 5)0.022
Resection margin (R0/R1)16/028/0-48/368/80.55519/222/20.700
Postoperative chemotherapy (yes/no)6/1015/130.30529/2236/400.29413/810/140.175
Table 5 Perioperative complications between extended and standard lymphadenectomy group in pancreatic head carcinoma patients at different T stages
VariableT1 stage
T2 stage
T3 stage
ELD group (n = 16)
SLD group (n = 28)
P value
ELD group (n = 51)
SLD group (n = 76)
P value
ELD group (n = 21)
SLD group (n = 24)
P value
Perioperative death011.000240.93800-
Postoperative complications4120.39114250.514950.111
Biochemical fistula130.961130.912100.467
Pancreatic fistula (grade B/C)030.463430.58500-
DGE240.7714100.349310.506
Diarrhea310.254122< 0.001710.031
Abdominal infection130.961580.895320.874
Abdominal hemorrhage011.000330.93800-
Table 6 Univariate analysis of long-term prognosis in pancreatic head carcinoma patients at T3 stage
Variables
Number (n = 45)
yr OS (%)
3-yr OS (%)
χ2
P value
Gender0.0040.949
Male2246.813.7
Female2354.110.8
Age (yr)2.1920.139
≤ 602260.220.1
> 602343.65.5
CA19-9 (U/mL)1.5040.220
≤ 37959.329.6
> 373648.97.5
Operation time (h)2.6470.104
≤ 101863.219.0
> 102742.56.1
Intraoperative blood loss (mL)0.2530.615
≤ 8003049.216.5
> 8001555.90
Tumor differentiation0.9960.318
Poorly2139.38.2
Moderately-highly2459.915.0
Lymph node metastasis5.5420.019
Yes3442.97.9
No1177.825.9
Positive lymph node count0.5690.451
≤ 33352.98.2
> 31246.323.1
Portal vein invasion4.1410.042
Yes3342.37.7
No1272.724.2
Resection margin0.0350.852
R04148.113.9
R1475.00
Extent of lymphadenectomy7.8430.005
ELD2165.321.8
SLD2436.10
Postoperative chemotherapy0.0270.869
Yes2341.511.9
No2261.212.4
Table 7 Cox multivariate regression analysis of long-term prognosis in pancreatic head carcinoma patients at T3 stage
Variables
RR
95%CI
P value
Lymph node metastasis1.9150.724-5.0630.190
Portal vein system invasion2.4711.028-5.9420.043
Extent of lymphadenectomy2.3951.065-5.3830.035